JPWO2019140266A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019140266A5 JPWO2019140266A5 JP2020538819A JP2020538819A JPWO2019140266A5 JP WO2019140266 A5 JPWO2019140266 A5 JP WO2019140266A5 JP 2020538819 A JP2020538819 A JP 2020538819A JP 2020538819 A JP2020538819 A JP 2020538819A JP WO2019140266 A5 JPWO2019140266 A5 JP WO2019140266A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- conjugate
- composition
- subject
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 claims description 55
- 206010028980 Neoplasm Diseases 0.000 claims description 47
- 239000000969 carrier Substances 0.000 claims description 31
- 239000003814 drug Substances 0.000 claims description 31
- 229940079593 drugs Drugs 0.000 claims description 26
- 239000012216 imaging agent Substances 0.000 claims description 26
- 229920001223 polyethylene glycol Polymers 0.000 claims description 26
- 239000003112 inhibitor Substances 0.000 claims description 17
- 230000002401 inhibitory effect Effects 0.000 claims description 17
- 238000009825 accumulation Methods 0.000 claims description 14
- 239000002202 Polyethylene glycol Substances 0.000 claims description 12
- 239000002738 chelating agent Substances 0.000 claims description 12
- 238000002600 positron emission tomography Methods 0.000 claims description 12
- 239000002105 nanoparticle Substances 0.000 claims description 10
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims description 9
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical group CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 claims description 8
- 239000002246 antineoplastic agent Substances 0.000 claims description 8
- 230000027455 binding Effects 0.000 claims description 8
- 238000003384 imaging method Methods 0.000 claims description 8
- 229920000642 polymer Polymers 0.000 claims description 8
- 230000014759 maintenance of location Effects 0.000 claims description 7
- 210000001519 tissues Anatomy 0.000 claims description 7
- 230000002792 vascular Effects 0.000 claims description 7
- 230000001839 systemic circulation Effects 0.000 claims description 6
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 claims description 5
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 5
- 101700007241 APOC4 Proteins 0.000 claims description 5
- 230000037250 Clearance Effects 0.000 claims description 5
- 101710038729 F2R Proteins 0.000 claims description 5
- 229960002949 Fluorouracil Drugs 0.000 claims description 5
- 101700036247 PARP1 Proteins 0.000 claims description 5
- 102100014579 PARP1 Human genes 0.000 claims description 5
- 101700053624 PARP2 Proteins 0.000 claims description 5
- 101700027237 PROA Proteins 0.000 claims description 5
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims description 5
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temodal Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 5
- 229960004528 Vincristine Drugs 0.000 claims description 5
- 239000000654 additive Substances 0.000 claims description 5
- 230000000996 additive Effects 0.000 claims description 5
- 101700004528 arp Proteins 0.000 claims description 5
- 230000035512 clearance Effects 0.000 claims description 5
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims description 5
- 229960001756 oxaliplatin Drugs 0.000 claims description 5
- 230000035699 permeability Effects 0.000 claims description 5
- 229960004964 temozolomide Drugs 0.000 claims description 5
- PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 claims description 5
- 229960000977 trabectedin Drugs 0.000 claims description 5
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 5
- XOZIUKBZLSUILX-GIQCAXHBSA-N (4S,7R,8S,9S,13Z,16S)-4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-[(E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-1-oxacyclohexadec-13-ene-2,6-dione Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 XOZIUKBZLSUILX-GIQCAXHBSA-N 0.000 claims description 4
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 4
- 229960000958 Deferoxamine Drugs 0.000 claims description 4
- 102000004459 Nitroreductases Human genes 0.000 claims description 4
- 108020001162 Nitroreductases Proteins 0.000 claims description 4
- 150000001408 amides Chemical class 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 4
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims description 4
- 238000003795 desorption Methods 0.000 claims description 4
- 230000001809 detectable Effects 0.000 claims description 4
- 229930013356 epothilones Natural products 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 238000006460 hydrolysis reaction Methods 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- 230000035772 mutation Effects 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 239000002777 nucleoside Substances 0.000 claims description 4
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 4
- 230000017854 proteolysis Effects 0.000 claims description 4
- 230000002797 proteolythic Effects 0.000 claims description 4
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 4
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims description 4
- 229940121358 tyrosine kinase inhibitors Drugs 0.000 claims description 4
- 230000035700 Clearance Rate Effects 0.000 claims description 3
- 229920002521 Macromolecule Polymers 0.000 claims description 3
- 230000001988 toxicity Effects 0.000 claims description 3
- 231100000419 toxicity Toxicity 0.000 claims description 3
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 claims description 3
- 102100000648 ATM Human genes 0.000 claims description 2
- 108060006202 ATM Proteins 0.000 claims description 2
- IUEWAGVJRJORLA-UHFFFAOYSA-N BMN673 Chemical compound CN1N=CN=C1C1C(NNC(=O)C2=CC(F)=C3)=C2C3=NC1C1=CC=C(F)C=C1 IUEWAGVJRJORLA-UHFFFAOYSA-N 0.000 claims description 2
- 102000036638 BRCA1 Human genes 0.000 claims description 2
- 108010042977 BRCA1 Protein Proteins 0.000 claims description 2
- 102000002280 BRCA2 Protein Human genes 0.000 claims description 2
- 108010000750 BRCA2 Protein Proteins 0.000 claims description 2
- 230000033616 DNA repair Effects 0.000 claims description 2
- 230000036231 pharmacokinetics Effects 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 230000002588 toxic Effects 0.000 claims description 2
- 231100000331 toxic Toxicity 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862617095P | 2018-01-12 | 2018-01-12 | |
| US62/617,095 | 2018-01-12 | ||
| US201862674483P | 2018-05-21 | 2018-05-21 | |
| US62/674,483 | 2018-05-21 | ||
| US201862700147P | 2018-07-18 | 2018-07-18 | |
| US62/700,147 | 2018-07-18 | ||
| US201862711423P | 2018-07-27 | 2018-07-27 | |
| US201862711421P | 2018-07-27 | 2018-07-27 | |
| US62/711,423 | 2018-07-27 | ||
| US62/711,421 | 2018-07-27 | ||
| US201862716788P | 2018-08-09 | 2018-08-09 | |
| US201862716796P | 2018-08-09 | 2018-08-09 | |
| US62/716,788 | 2018-08-09 | ||
| US62/716,796 | 2018-08-09 | ||
| PCT/US2019/013306 WO2019140266A1 (en) | 2018-01-12 | 2019-01-11 | Protocol for minimizing toxicity of combination dosages and imaging agent for verification |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021510701A JP2021510701A (ja) | 2021-04-30 |
| JPWO2019140266A5 true JPWO2019140266A5 (ru) | 2022-03-16 |
Family
ID=67218383
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020538819A Pending JP2021510701A (ja) | 2018-01-12 | 2019-01-11 | 併用投与の毒性を最小化するためのプロトコルおよび検証用のイメージング剤 |
| JP2020538844A Pending JP2021510702A (ja) | 2018-01-12 | 2019-01-11 | 相乗的がん治療 |
| JP2023186470A Pending JP2024012442A (ja) | 2018-01-12 | 2023-10-31 | 相乗的がん治療 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020538844A Pending JP2021510702A (ja) | 2018-01-12 | 2019-01-11 | 相乗的がん治療 |
| JP2023186470A Pending JP2024012442A (ja) | 2018-01-12 | 2023-10-31 | 相乗的がん治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US20200360545A1 (ru) |
| EP (2) | EP3737383A4 (ru) |
| JP (3) | JP2021510701A (ru) |
| KR (2) | KR20200109345A (ru) |
| CN (2) | CN111587115A (ru) |
| AU (2) | AU2019208024A1 (ru) |
| CA (2) | CA3087967A1 (ru) |
| MX (3) | MX2020007442A (ru) |
| RU (1) | RU2020126774A (ru) |
| WO (2) | WO2019140266A1 (ru) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220052918A (ko) | 2019-07-10 | 2022-04-28 | 싸이브렉사 2, 인크. | 치료제로서의 사이토톡신의 펩티드 접합체 |
| JP2022541747A (ja) | 2019-07-10 | 2022-09-27 | サイブレクサ ３，インコーポレイテッド | 治療薬としての微小管標的化剤のペプチドコンジュゲート |
| US20220331437A1 (en) * | 2019-08-28 | 2022-10-20 | Prolynx Llc | Conjugated inhibitors of dna damage response |
| WO2024031005A2 (en) * | 2022-08-04 | 2024-02-08 | Prolynx Llc | Treating cancer with long-acting topoisomerase i inhibitor |
| WO2024030998A2 (en) * | 2022-08-04 | 2024-02-08 | Prolynx Llc | Methods of treating cancer with long-acting topoisomerase i inhibitor |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998030575A1 (en) | 1997-01-08 | 1998-07-16 | Proligo Llc | Bioconjugation of macromolecules |
| US7850990B2 (en) | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| CA2491661A1 (en) | 2002-07-12 | 2004-01-22 | Biomarin Pharmaceutical Inc. | The use of isocyanate linkers to make hydrolyzable active agent biopolymer conjugates |
| ES2488841T3 (es) | 2002-10-31 | 2014-08-29 | Nippon Kayaku Kabushiki Kaisha | Derivados de alto peso molecular de camptotecinas |
| US20040247624A1 (en) | 2003-06-05 | 2004-12-09 | Unger Evan Charles | Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility |
| KR101200729B1 (ko) | 2003-09-17 | 2012-11-13 | 넥타르 테라퓨틱스 | 다분지형 고분자 전구약물 |
| US7462627B2 (en) | 2006-02-09 | 2008-12-09 | Enzon Pharmaceuticals, Inc. | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers |
| CA2662981A1 (en) | 2006-09-15 | 2008-03-20 | Enzon Pharmaceuticals, Inc. | Targeted polymeric prodrugs containing multifunctional linkers |
| CN102105156B (zh) * | 2008-05-22 | 2016-05-25 | 特拉维夫大学拉莫特有限公司 | 连接有治疗活性剂和血管生成靶向部分的聚合物的新型缀合物及其在治疗血管生成相关疾病中的用途 |
| CN102076331B (zh) | 2008-06-26 | 2013-12-18 | 普罗林科斯有限责任公司 | 具有可控的药物释放速率的前药和药物-大分子轭合物 |
| AU2009307922A1 (en) | 2008-10-21 | 2010-04-29 | Enzon Pharmaceuticals, Inc. | Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin |
| US20100126866A1 (en) | 2008-11-18 | 2010-05-27 | Baxter Healthcare S.A. | Methods of determining polydispersity and/or molecular weight distribution of a polyethylene glycol sample |
| CN102448469A (zh) | 2009-05-28 | 2012-05-09 | 摩萨纳医疗有限公司 | 包括具有可变的释放速率的连接物的聚缩醛(酮)-药物共轭物 |
| US20130143909A1 (en) * | 2009-11-18 | 2013-06-06 | Nektar Therapeutics | Acid Salt Forms of Polymer-Drug Conjugates and Alkoxylation Methods |
| WO2011140376A1 (en) | 2010-05-05 | 2011-11-10 | Prolynx Llc | Controlled drug release from dendrimers |
| JP5964815B2 (ja) | 2010-05-05 | 2016-08-03 | プロリンクス リミテッド ライアビリティ カンパニー | 固体担体からの放出制御薬物 |
| JP5977229B2 (ja) * | 2010-05-05 | 2016-08-24 | プロリンクス リミテッド ライアビリティ カンパニー | 巨大分子共役体からの徐放 |
| TW201215412A (en) | 2010-08-30 | 2012-04-16 | Sun Pharma Advanced Res Co Ltd | Stable pharmaceutical composition |
| RU2017127088A (ru) * | 2010-11-16 | 2019-02-04 | Эррэй Биофарма Инк. | Комбинация ингибиторов чекпойнт-киназы 1 и ингибиторов киназы wee 1 |
| WO2012088282A1 (en) | 2010-12-21 | 2012-06-28 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds |
| EP2751088B1 (en) | 2011-09-30 | 2016-04-13 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| IN2014MN01819A (ru) * | 2012-03-05 | 2015-07-03 | Univ Ramot | |
| TWI486341B (zh) * | 2012-05-18 | 2015-06-01 | Univ Kaohsiung Medical | 抑制ａｔｒ與ｆａｎｃｄ２激活之組成物與方法 |
| WO2014194289A1 (en) * | 2013-05-31 | 2014-12-04 | Nektar Therapeutics | Method for predicting and evaluating responsiveness to cancer treatment with dna-damaging chemotherapeutic agents |
| DK3052101T3 (da) * | 2013-10-04 | 2019-12-16 | Prolynx Llc | Konjugater af sn-38 med langsom frigivelse |
| WO2015066053A2 (en) * | 2013-10-28 | 2015-05-07 | Synta Pharmaceuticals Corp. | Targeted therapeutics |
| WO2015118338A1 (en) * | 2014-02-07 | 2015-08-13 | Mission Therapeutics Limited | Methods for exploiting synthetic lethality and chemo-sensitisation in dna damage response (ddr) pathways |
| US20150343100A1 (en) * | 2014-05-28 | 2015-12-03 | Memorial Sloan Kettering Cancer Center | Bimodal fluorophore-labeled liposomes and associated methods and systems |
| JP6342575B2 (ja) * | 2014-08-13 | 2018-06-13 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 脳腫瘍への選択的デンドリマー送達 |
| WO2016028636A1 (en) | 2014-08-16 | 2016-02-25 | Memorial Sloan Kettering Cancer Center | Helical polycarbodiimide polymers and associated imaging, diagnostic, and therapeutic methods |
| JP6378584B2 (ja) | 2014-08-29 | 2018-08-22 | キヤノン株式会社 | 通信システム、画像処理装置、画像処理装置の制御方法、及びプログラム |
| US10196412B2 (en) * | 2014-12-24 | 2019-02-05 | The Board Of Trustees Of The Leland Stanford Junior University | Probe for imaging PARP-1 activity |
| SI3560924T1 (sl) | 2015-04-02 | 2021-08-31 | Merck Patent Gmbh | Imidazolonilkinolini in njihova uporaba kot zaviralci ATM-kinaze |
| EP3280454A1 (en) * | 2015-04-07 | 2018-02-14 | Memorial Sloan Kettering Cancer Center | Nanoparticle immunoconjugates |
| CA3022354A1 (en) * | 2015-04-28 | 2016-11-03 | Sanford Burnham Prebys Medical Discovery Institute At Lake Nona | Methods and compositions for theranostic nanoparticles |
| CA2992789A1 (en) | 2015-08-20 | 2017-02-23 | Ipsen Biopharm Ltd. | Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment |
| US10821195B2 (en) | 2015-09-10 | 2020-11-03 | Memorial Sloan Kettering Cancer Center | Compositions for therapeutics, targeted PET imaging and methods of their use |
| WO2017059397A1 (en) | 2015-10-01 | 2017-04-06 | Whitehead Institute For Biomedical Research | Labeling of antibodies |
| CN108697666A (zh) | 2016-02-29 | 2018-10-23 | 辛塔制药公司 | 用于治疗卵巢癌的组合疗法 |
| WO2017172678A1 (en) * | 2016-03-30 | 2017-10-05 | Merrimack Pharmaceuticals, Inc. | Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan |
| CN109310385A (zh) * | 2016-04-27 | 2019-02-05 | 免疫医疗公司 | 抗trop-2-sn-38抗体药物缀合物用于检查点抑制剂复发/难治的肿瘤的疗法的功效 |
| KR20190003630A (ko) * | 2016-04-29 | 2019-01-09 | 메모리얼 슬로안 케터링 캔서 센터 | 악성 뇌 종양에서의 표적화된 입자 침투, 분포, 및 반응을 위한 조성물 및 방법 |
| CN106084005B (zh) | 2016-06-15 | 2020-02-14 | 广州军区广州总医院 | 靶向生长抑素受体的Al18F-NOTA-PEG6-TATE及其制备方法和应用 |
| CN107050471A (zh) * | 2016-12-27 | 2017-08-18 | 中国药科大学 | 基于富勒烯的靶向且具有快速清除特征的显像纳米探针及其制备方法和应用 |
-
2019
- 2019-01-11 MX MX2020007442A patent/MX2020007442A/es unknown
- 2019-01-11 KR KR1020207023338A patent/KR20200109345A/ko not_active Application Discontinuation
- 2019-01-11 JP JP2020538819A patent/JP2021510701A/ja active Pending
- 2019-01-11 EP EP19738883.8A patent/EP3737383A4/en active Pending
- 2019-01-11 MX MX2020007306A patent/MX2020007306A/es unknown
- 2019-01-11 CN CN201980008227.1A patent/CN111587115A/zh active Pending
- 2019-01-11 US US16/961,633 patent/US20200360545A1/en not_active Abandoned
- 2019-01-11 EP EP19738881.2A patent/EP3737416A4/en active Pending
- 2019-01-11 AU AU2019208024A patent/AU2019208024A1/en active Pending
- 2019-01-11 RU RU2020126774A patent/RU2020126774A/ru unknown
- 2019-01-11 CA CA3087967A patent/CA3087967A1/en active Pending
- 2019-01-11 US US16/961,640 patent/US11730836B2/en active Active
- 2019-01-11 JP JP2020538844A patent/JP2021510702A/ja active Pending
- 2019-01-11 AU AU2019206623A patent/AU2019206623A1/en active Pending
- 2019-01-11 KR KR1020207023337A patent/KR20200110377A/ko not_active Application Discontinuation
- 2019-01-11 CA CA3087628A patent/CA3087628A1/en active Pending
- 2019-01-11 WO PCT/US2019/013306 patent/WO2019140266A1/en unknown
- 2019-01-11 WO PCT/US2019/013314 patent/WO2019140271A2/en unknown
- 2019-01-11 CN CN201980008252.XA patent/CN111587126A/zh active Pending
-
2020
- 2020-07-13 MX MX2023005786A patent/MX2023005786A/es unknown
-
2023
- 2023-03-07 US US18/118,650 patent/US20230321286A1/en active Pending
- 2023-07-11 US US18/220,742 patent/US20240082436A1/en active Pending
- 2023-10-31 JP JP2023186470A patent/JP2024012442A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Indoria et al. | Recent advances in theranostic polymeric nanoparticles for cancer treatment: A review | |
| Luo et al. | Cross-linked and biodegradable polymeric system as a safe magnetic resonance imaging contrast agent | |
| Sharma et al. | Dendrimer nanoarchitectures for cancer diagnosis and anticancer drug delivery | |
| Guo et al. | Image-guided and tumor-targeted drug delivery with radiolabeled unimolecular micelles | |
| Yin et al. | Poly (iohexol) nanoparticles as contrast agents for in vivo X-ray computed tomography imaging | |
| Cabral et al. | Supramolecular nanodevices: from design validation to theranostic nanomedicine | |
| Veiseh et al. | Specific targeting of brain tumors with an optical/magnetic resonance imaging nanoprobe across the blood-brain barrier | |
| Yigit et al. | Magnetic nanoparticles for cancer diagnosis and therapy | |
| Faure et al. | Control of the in vivo biodistribution of hybrid nanoparticles with different poly (ethylene glycol) coatings | |
| Xin et al. | Bioinspired coordination micelles integrating high stability, triggered cargo release, and magnetic resonance imaging | |
| Zhang et al. | Shape effects of cylindrical versus spherical unimolecular polymer nanomaterials on in vitro and in vivo behaviors | |
| Nabi et al. | Mucin-1 conjugated polyamidoamine-based nanoparticles for image-guided delivery of gefitinib to breast cancer | |
| Lim et al. | The role of the size and number of polyethylene glycol chains in the biodistribution and tumor localization of triazine dendrimers | |
| CN105407927A (zh) | 用于引导放射治疗的凝胶配方 | |
| RU2020126774A (ru) | Протокол для сведения к минимуму токсического воздействия комбинированных доз и визуализирующий агент для подтверждения | |
| KR101384991B1 (ko) | 온도 및 피에이치 민감성 하이드로젤의 인터벤셔널 인젝션에 기반한 간암치료용 약물전달체 | |
| US20120087859A1 (en) | Nanocarrier having enhanced skin permeability, cellular uptake and tumour delivery properties | |
| Zhou et al. | Gd3+-1, 4, 7, 10-tetraazacyclododecane-1, 4, 7-triacetic-2-hydroxypropyl-β-cyclodextrin/pluronic polyrotaxane as a long circulating high relaxivity MRI contrast agent | |
| Hue et al. | Distribution and accumulation of Cy5. 5-labeled thermally cross-linked superparamagnetic iron oxide nanoparticles in the tissues of ICR mice | |
| Caminade et al. | Dendritic metal complexes for bioimaging. Recent advances | |
| Goos et al. | Design and preclinical evaluation of nanostars for the passive pretargeting of tumor tissue | |
| Zhao et al. | Polyethylenimine-based theranostic nanoplatform for glioma-targeting single-photon emission computed tomography imaging and anticancer drug delivery | |
| Zanganeh et al. | Immunoengineering in glioblastoma imaging and therapy | |
| Ferrari et al. | Biocompatible polymer nanoformulation to improve the release and safety of a drug mimic molecule detectable via ICP-MS | |
| Ali et al. | Advances in nanoparticles as anticancer drug delivery vector: need of this century |